- Seborrheic keratosis (SK), a common non-cancerous skin condition, is increasingly treated using advanced procedures such as cryotherapy, curettage or electrocautery, ablative laser surgery, shave biopsy, focal chemical peels, and topical medications. These methods offer effective removal, minimal discomfort, and improved cosmetic outcomes, thereby supporting their growing adoption across dermatology clinics and hospitals.
- The global demand for SK treatment is largely driven by the rising geriatric population, which is more prone to SK, alongside increased awareness of skin health, growing availability of dermatology services, and the influence of cosmetic dermatology trends encouraging the removal of benign lesions for aesthetic reasons.
- North America held the largest revenue share of 38.7% in 2024, owing to a high incidence of SK, early adoption of advanced treatment technologies, well-established dermatological infrastructure, and increased patient expenditure on skin-related procedures. The United States alone accounted for over USD 650 million in SK treatment revenue in 2024.
- Asia-Pacific is projected to be the fastest-growing region from 2025 to 2035, driven by a large underserved patient population, increasing urbanization, rising disposable incomes, and expanding dermatology clinics and aesthetic centers in countries like China, India, and South Korea.
- Cryotherapy is expected to dominate the treatment segment, accounting for approximately 34.5% of the global market share in 2025, due to its high effectiveness, affordability, and ease of application in both outpatient and homecare settings
